CRISPR/Cas9 uses for zebrafish targeted mutagenesis and genome editing

ZeClinics, a Spanish Biotech company specialized in the use of zebrafish for drug discovery and biomedicine, receives the patent license for CRISPR/Cas9 uses for zebrafish targeted mutagenesis and genome editing from the Broad Institute, MIT and Harvard University.

With that ZeClinics becomes one of the first worldwide companies providing the Zebrafish Genome Editing services to the biotech, pharma and biomedical industries, bringing the innovative concept of preclinical disease modeling through the tiny and powerful fish.

Up to 87% of genes implicated in human diseases have functional homologues in zebrafish. Genome-editing technologies (CRISPR/Cas9) allows for the generation of mutants, genetic disease models for a deeper understanding on the disease biology and high-throughput drug discovery.

Researchers, scientists and drug maker firms, dealing with complex diseases and Genome Wide Association Studies (GWAS) studies, Rare Diseases, Next Generation Sequencing (NGS) projects will benefit from ZeClinics’ CRISPR services and will accelerate their science.

ZeClinics provides its expertise in genomic manipulation and zebrafish biology for generating mutants, transgenics, knock-out and knock-in lines, phenotyping and use them for custom drug screenings and biomedical research.